(Q38088306)

28 August 2017

Recent initiatives and strategies to developing new drugs for tropical parasitic diseases (English)

1 reference

28 August 2017

Dietmar Steverding

2

0 references

author name string

Conor R Caffrey

series ordinal

1

1 reference

PubMed ID

23480221

28 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Drug Discovery

28 August 2017

1 reference

28 August 2017

3

1 reference

28 August 2017

173-186

1 reference

28 August 2017

2

1 reference

Global framework on essential health R&D.

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug development for neglected diseases: a deficient market and a public-health policy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Virtual drug discovery and development for neglected diseases through public-private partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug discovery and development for neglected parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Innovative lead discovery strategies for tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Target assessment for antiparasitic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Chemotherapy of human African trypanosomiasis: current and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drugs and drug resistance in African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Specific chemotherapy of Chagas disease: controversies and advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Therapy of intestinal protozoa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drugs for the control of parasitic diseases: current status and development in schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Chemotherapy of schistosomiasis: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Mass drug treatment for lymphatic filariasis and onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Human gastrointestinal helminth infections: are they now neglected diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Advances in the discovery and development of trematocidal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Challenges in drug discovery for novel antifilarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Target identification and validation for anthelmintic discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Control of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Functional genomics: identifying drug targets for parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Genomic filtering: an approach to discovering novel antiparasitics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Isoprenoid biosynthesis of the apicoplast as drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

RNA interference for analysis of gene function in trypanosomatids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Protein kinases as targets for antiparasitic chemotherapy drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug repositioning: identifying and developing new uses for existing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

21 January 2018

New uses for old drugs

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Anti-trypanosomal activities of DNA topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

A clinical drug library screen identifies astemizole as an antimalarial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Searching for new antimalarial therapeutics amongst known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

High-throughput Plasmodium falciparum growth assay for malaria drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

An improved and highly sensitive microfluorimetric method for assessing susceptibility of Plasmodium falciparum to antimalarial drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Advances and perspectives in Leishmania cell based drug-screening procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Schistosomes: challenges in compound screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Access to essential drugs in poor countries: a lost battle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

The burden of disease among the global poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Public-private partnership: from there to here

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

A breakthrough in R&D; for neglected diseases: new ways to get the drugs we need

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Public-private partnerships for public health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Identification of an antimalarial synthetic trioxolane drug development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

The mode of action of the antimalarial artemisinin and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Synthesis of tetrasubstituted ozonides by the Griesbaum coozonolysis reaction: diastereoselectivity and functional group transformations by post-ozonolysis reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Medicines for Malaria Venture: sustaining antimalarial drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

The development of Lapdap, an affordable new treatment for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Cysteine proteases of malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Cysteine proteinase inhibitors as therapy for parasitic diseases: advances in inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Synthesis and antiprotozoal activity of aza-analogues of furamidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.173

21 January 2018

Identifiers

DOI

10.1517/17460441.3.2.173

1 reference

release_7pxxccpwnzg4pjph2ewd6ixewa

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7pxxccpwnzg4pjph2ewd6ixewa

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23480221

1 reference

PubMed ID

23480221